← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Zoneone Pharma, Inc.
San Francisco, CA
$3,123,049
Total funding
6
Grants
Funding over time
peak $1.2M · FY2012–16$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,405,242 · 5
FDA$717,807 · 1
By mechanism
R44$1,491,193 · 1
U01$717,807 · 1
R43$399,130 · 2
R41$298,920 · 1
N43$215,999 · 1
Investigators at Zoneone Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$956,715
R44 · FY2016 · HD
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$534,478
R44 · FY2015 · HD
Development of a Liposome Doxorubicin Product Drug Release Assay$467,811
U01 · FY2013 · FD
Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells$298,920
R41 · FY2015 · CA
Development of a Liposome Doxorubicin Product Drug Release Assay$249,996
U01 · FY2014 · FD
Non-irritating Sustained Release Cysteamine Eye Drops to Treat Cystinosis$238,466
R43 · FY2016 · EY
OTHER FUNCTIONS - R&D BIOMEDICAL (BASIC RESEARCH)$215,999
N43 · FY2012 · CA
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload$160,664
R43 · FY2013 · HD